Increased T286/7 phosphorylation of CaMKII is noted in TRAIL-resistant melanoma cells [125], lung cancer oncospheres [103], osteosarcoma [101,102], leukaemia stem cells [126], AML patient blasts [98], primary and metastatic breast tumours compared to normal adjacent breast tissue [100] and in metastatic gastric cancers compared to non-metastatic tissues [105], indicating that enhanced CaMKII activity is a feature of cancers, and is also associated with metastatic disease. This evidence concerns the gene CAMK2G and metastatic neoplasm.